Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 1, 2005, Pages 111-113

  Sirvent, Juan Luis Gomez ^a   Socas, Maria Mar Alonso ^a   Calzadilla, Carlos Hernandez ^a   Lirola, Ana M Lopez ^a   Valls, Maria Remedios Aleman ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; DRUG WITHDRAWAL; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; VIREMIA;

EID: 24144477519     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000174650.33159.22     Document Type: Letter

References (15)

1. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189:1452-1465.
2. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000;14:2877-2887.
3. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1030-1037.
4. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
5. García F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F79-86.
6. Hirschel B. Beware of drug holidays before HIV salvage therapy. N Engl J Med. 2003;349:827-828.
7. Devereux HL, Youle M, Johnson M, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13:F123-F127.
8. Verhofstede C, Van Wanzeele F, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 1999;13:2541-2546.
9. Batisse D, Karmochkine M, Si Mohamed A, et al. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy. AIDS. 1998;12:824-825.
10. Papasavvas E, Grant R, Sun J. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS. 2003;17:2337-2343.
11. Deeks S, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS. 2002;16(Suppl 4): S157-S169.
12. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS. 2002;16:895-899.
13. Skiest DL, Morrow P, Allen B, et al. It is safe to stop antiretroviral therapy in patients with pre-antiretroviral CD4 cell counts >250 cells/μL. J Acquir Immune Defic Syndr. 2004;37:1351-1357.
14. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS. 2004;18:459-464.
15. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.